Sickle Cell Gene Editing Therapy
Doctors at TriStar Centennial are participating in a national, clinical trial and using groundbreaking gene-editing therapy to help sickle cell patients in Tennessee.
Doctors at TriStar Centennial are participating in a national, clinical trial and using groundbreaking gene-editing therapy to help sickle cell patients in Tennessee.
AbstractAdagrasib, an irreversible, selective KRASG12C inhibitor, may be an effective treatment in KRASG12C-mutated colorectal cancer, particularly when combined with an anti-EGFR antibody. In this analysis…
In some parts of England, there are proposals to divide NHS primary care services. NHS England’s strategy aims to separate patients with “same-day” acute care…
The OncoAlert Newsletter is now out for June 23-29, 2023
Vinay Prasad, MD MPH; Physician & Professor Hematologist/ OncologistProfessor of Epidemiology, Biostatistics and MedicineAuthor of 450+ Peer Reviewed papers,…
In February, ASCO named molecular profiling driving progress in gastrointestinal cancers as its “Advance of the Year.” According to the American Cancer Society, taken collectively,…
Background Adoptive cell therapy, such as chimeric antigen receptor (CAR)-T cell therapy, has improved patient outcomes for hematological malignancies. Currently, four of the six FDA-approved…
We invite you to submit your clinical cases or burning questions related to endometrial cancer management, and particularly encourage cases from trainees or fellows and…
AbstractPurpose:. To examine whether overall survival (OS) differs for male and female patients with advanced soft-tissue sarcoma (STS).Experimental Design:. The study included patients from Kaiser…
Palliative care (PC) plays a critical role in managing the difficulties associated with genitourinary malignancies. Its primary aim is to improve the overall health of…
Immune checkpoint inhibitors improve the efficacy of first-line chemotherapy for patients with programmed death-ligand 1 (PD-L1)-positive unresectable locally advanced/metastatic triple-negative breast cancer (aTNBC), but randomised…